Current News

Contact | Print version | Send article | RSS feed

ARIUS Receives Six Key US Patents
Strengthens Intellectual Property Portfolio on Lead Programs and Antibody Assets

30 Nov 2006 - ARIUS Research Inc. announced that it has received Notices of Allowance from the United States Patent and Trademark Office for patents on their lead antibody, ARH460-16-2, targeting the CD44 antigen implicated as markers of cancer stem cells in breast and prostate cancer plus separate patents covering antibodies to the CD63, CD59 and MCSP antigens.
 
The new patents cover the antibody molecules and various uses of each antibody and other similar antibodies to treat cancers such as ovarian, prostate and breast cancer. In addition, ARIUS has patent claims covering epitopes or specific parts of a cancer antigen target. According to ARIUS, this patent approach represents a large step up in value over more general target coverage because it is the epitope that determines what a cell will do when an antibody binds to it. In ARIUS' case, functional antibodies bind to epitopes that signal a cancer cell to die.